Amarin Gains 75% On Drug Data (AMRN)

Amarin Corp. AMRN is the largest percentage gainer on any stock exchange on Monday, rising around 75% to $15.30. The company announced positive clinical data from its ANCHOR trial on its drug candidate AMR101, which is used to treat high triglycerides in patients. The Phase III trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses of AMR101. The drug is a prescription grade Omega-3 fatty acid, comprising not less than 96% ultra pure ethyl ester of eicosapentaenoic acid (ethyl-EPA). Amarin Corporation plc (Amarin) is a clinical-stage biopharmaceutical company focused on developing improved treatments for cardiovascular disease. The Company's development programs capitalize in the field of lipid science and the therapeutic benefits of essential fatty acids in cardiovascular disease. The company has a market cap of $1.92 billion.